Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS)

Introduction

Study characteristics:

• randomized, placebo-controlled trial
• 6,105 individuals with previous stroke or TIA
• 172 centres in Asia, Australasia, and Europe
• 30% of participants were women
• 4 years follow-up

Groups:

• perinodopril 4 mg QD plus placebo
• perinodopril 4 mg QD plus diuretic (indapamide)
• placebo

Results:

• 10% of treated groups suffered stroke vs 14% of placebo group
• stroke risk reduction occurred regardless of whether subject was hypertensive
• subjects treated with perinodopril plus indapamide had significantly fewer recurrent strokes than subjects treated with placebo (8% vs 14%)
• perinodopril alone afforded no benefit for stroke reduction
• the antihypertensive effect of perinodopril plus indapamide was greater than that of perinodopril alone 12/4 mm Hg vs 5/3 mm Hg

More general terms

• hypertension clinical trials